Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results
Guardat en:
| Publicat a: | Cancer Medicine vol. 14, no. 17 (Sep 1, 2025) |
|---|---|
| Autor principal: | |
| Altres autors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Publicat: |
John Wiley & Sons, Inc.
|
| Matèries: | |
| Accés en línia: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3248840692 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2045-7634 | ||
| 024 | 7 | |a 10.1002/cam4.71173 |2 doi | |
| 035 | |a 3248840692 | ||
| 045 | 0 | |b d20250901 | |
| 084 | |a 233228 |2 nlm | ||
| 100 | 1 | |a Rubio‐Briones, J. |u Hospital VITHAS 9 de Octubre, Valencia, Spain | |
| 245 | 1 | |a Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results | |
| 260 | |b John Wiley & Sons, Inc. |c Sep 1, 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a ABSTRACT Patients and Methods In this multicenter longitudinal study, data from the Spanish Register in AS (AEU‐PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow‐up strategies. Results A total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow‐up visits was 6.03 months. Over a median follow‐up of 62 months (Q1–3: 43.78–85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, with 3 due to prostate cancer progression and 196 attributed to other causes. At 2 and 5 years, pathological progression‐free survival, metastasis‐free survival, and active treatment‐free survival were 68% and 51%, 99% and 99%, and 70% and 50%, respectively. Conclusions Midterm oncological outcomes of AS in Spain align with major international series. We denote underuse of guideline recommendations such as use of MRI or TP Bx for initial PCa characterization. Collaborative efforts are crucial in the search for algorithms, new imaging, or biomarkers to refine indications and transition to active treatments. Trial Registration ClinicalTrials.gov identifier: NCT02865330 | |
| 651 | 4 | |a Spain | |
| 653 | |a Patients | ||
| 653 | |a Tomography | ||
| 653 | |a Magnetic resonance imaging | ||
| 653 | |a Metastasis | ||
| 653 | |a Biopsy | ||
| 653 | |a Costs | ||
| 653 | |a Mortality | ||
| 653 | |a Prostate cancer | ||
| 653 | |a Surveillance | ||
| 653 | |a Metastases | ||
| 653 | |a Survival | ||
| 653 | |a Risk groups | ||
| 653 | |a Aging | ||
| 653 | |a Ultrasonic imaging | ||
| 700 | 1 | |a Borque‐Fernando, A. |u Hospital Miguel Servet, IIS‐Aragon, Zaragoza, Spain | |
| 700 | 1 | |a Esteban Escaño, L. M. |u Hospital Escuela Universitaria La Almunia, Zaragoza, Spain | |
| 700 | 1 | |a Wong, A. |u Hospital Instituto Valenciano de Oncología, Valencia, Spain | |
| 700 | 1 | |a Guijarro Cascales, A. |u Hospital Fundación Alcorcón, Madrid, Spain | |
| 700 | 1 | |a Gómez Gómez, E. |u Hospital Reina Sofía, Córdoba, Spain | |
| 700 | 1 | |a Gil Fabra, J. M. |u Hospital Miguel Servet, IIS‐Aragon, Zaragoza, Spain | |
| 700 | 1 | |a Sanguedolce, F. |u Hospital Fundación Puigvert, Barcelona, Spain | |
| 700 | 1 | |a Gomez‐Veiga, F. |u Hospital Universitario de Salamanca, Salamanca, Spain | |
| 700 | 1 | |a López González, P. A. |u Hospital Virgen de la Arraixaca, Murcia, Spain | |
| 700 | 1 | |a Plata Bello, A. |u Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain | |
| 700 | 1 | |a Rodríguez García, N. |u Hospital Son Llatzer, Baleares, Spain | |
| 700 | 1 | |a Montesino Semper, M. |u Hospital Virgen del Camino, Navarra, Spain | |
| 700 | 1 | |a Suárez Novo, J. F. |u Hospital Universitario Bellvitge, Barcelona, Spain | |
| 700 | 1 | |a Hajianfar, R. |u Hospital Moises Broggi, Barcelona, Spain | |
| 700 | 1 | |a Fumadó Ciutat, L. l. |u Hospital del Mar, Barcelona, Spain | |
| 700 | 1 | |a González Alfaro, A. |u Hospital Móstoles, Madrid, Spain | |
| 700 | 1 | |a Duarte Ojeda, J. M. |u Hospital 12 de Octubre, Madrid, Spain | |
| 700 | 1 | |a Bono Ariño, A. |u Hospital San Jorge, Huesca, Spain | |
| 700 | 1 | |a Quicios Dorado, C. |u Hospital Fundación Jiménez Díaz, Madrid, Spain | |
| 700 | 1 | |a Loizaga Iriarte, A. |u Hospital Basurto, Vizcaya, Spain | |
| 700 | 1 | |a García Fadrique, G. |u Hospital Manises, Valencia, Spain | |
| 700 | 1 | |a Giménez Bachs, J. M. |u Hospital Universitario Albacete, Albacete, Spain | |
| 700 | 1 | |a García Barreras, S. |u Hospital Ramón y Cajal, Madrid, Spain | |
| 700 | 1 | |a Pallas Costa, Y. |u Hospital General Universitario, Valencia, Spain | |
| 700 | 1 | |a Vilaseca Cabo, A. |u Hospital Clínic, Barcelona, Spain | |
| 700 | 1 | |a Rodrigo Aliaga, M. |u Hospital General Universitario, Castellón, Spain | |
| 700 | 1 | |a Campanario Pérez, F. |u Hospital Complejo Asistencial Universitario, Palencia, Spain | |
| 700 | 1 | |a Servián, P. |u Hospital Germans Trias i Pujol, Barcelona, Spain | |
| 700 | 1 | |a Campá Bortoló, J. M. |u Hospital Universitario de Araba, Alava, Spain | |
| 700 | 1 | |a Soto Delgado, M. |u Hospital Puerta del Mar, Cádiz, Spain | |
| 700 | 1 | |a Rodríguez de Ledesma, J. M. |u Hospital CST Terrasa, Barcelona, Spain | |
| 700 | 1 | |a Sánchez Rodríguez, C. |u Hospital Reina Sofía, Murcia, Spain | |
| 700 | 1 | |a Chantada Abal, V. |u Hospital CHUAC, A Coruña, Spain | |
| 700 | 1 | |a Hernández Martínez, Y. E. |u Hospital Manacor, Baleares, Spain | |
| 700 | 1 | |a Herrera Imbroda, B. |u UGC Intercentros Urología Hospitales Universitarios Virgen de la Victoria y Regional, Málaga, Spain | |
| 700 | 1 | |a Dolezal, P. |u Hospital Barbastro, Huesca, Spain | |
| 700 | 1 | |a Gual Frau, J. |u Hospital Xátiva, Valencia, Spain | |
| 700 | 1 | |a Medrano Llorente, P. |u Hospital Clínico Lozano Blesa, Zaragoza, Spain | |
| 700 | 1 | |a Moreno Jiménez, J. |u Complejo Hospitalario, Jaen, Spain | |
| 700 | 1 | |a Serrano Uribe, J. S. |u Hospital Universitario Príncipe de Asturias, Madrid, Spain | |
| 700 | 1 | |a Congregado Ruiz, C. B. |u Hospital Universitario Vírgen del Rocío, Sevilla, Spain | |
| 700 | 1 | |a Reyes, A. |u Hospital Calatayud, Ernest Lluch, Zaragoza, Spain | |
| 700 | 1 | |a Fernández Aparicio, T. |u Hospital Morales Messeguer, Murcia, Spain | |
| 700 | 1 | |a García Rodríguez, J. |u Hospital Universitario Central, Asturias, Spain | |
| 700 | 1 | |a Cuadras Solé, M. |u Hospital Vall d Hebrón, Barcelona, Spain | |
| 700 | 1 | |a García Seguí, A. |u Hospital General Universitario Elche, Alicante, Spain | |
| 700 | 1 | |a Pacheco Bru, J. J. |u Hospital San Juan, Alicante, Spain | |
| 700 | 1 | |a Mayor de Castro, J. |u Hospital HGU Gregorio Marañón, Madrid, Spain | |
| 700 | 1 | |a Mira Moreno, A. |u Hospital General de Elda, Alicante, Spain | |
| 700 | 1 | |a Molina Suárez, J. L. |u Hospital Vírgen del Puerto, Extremadura, Spain | |
| 773 | 0 | |t Cancer Medicine |g vol. 14, no. 17 (Sep 1, 2025) | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3248840692/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3248840692/fulltext/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3248840692/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch |